HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $54 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Anavex Life Sciences (NASDAQ:AVXL) and maintained a $54 price target.
June 29, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anavex Life Sciences has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $54.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in Anavex Life Sciences. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100